BAY2010112 (AMG212, MT112) and MOR209/ES414 are prostate-specific membrane antigen (PSMA)/CD3 BiTEs that are being investigated in phase I clinical trials in patients with castration-resistant prostate cancer (NCT01723475, NCT02262910). Here, FOLH1 is linked to prostate cancer.